INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago

Results

80,116 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
KL
Kirgan Danielle L.EVP, Chief HR Officer
MMacy's, Inc.
Option exercise
M—
8,539 sh
Mar 24, 2026Mar 26, 2026
Page 1311 of 2003
← PrevNext →
traded Mar 24, 2026
+2d
SEC Form 4

Evidence

9
HM
Hancock MarkDirector, Co Fndr; Int CFO; Exec V Chair, 10% Owner
PACSPACS Group, Inc.
Grant or award
A—
98.2K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

8
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$104K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

8
BE
Bowe Patrick E.Director
ANDEAndersons, Inc.
Open-market sale · 10b5-1 plan
SELL$58K
800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

8
LR
Low RussellDirector, PRESIDENT AND CEO
ACLSAXCELIS TECHNOLOGIES INC
Open-market sale · 10b5-1 plan
SELL$112K
1,244 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

6
OD
Owens Bradley D.General Counsel
ZANDZGZILLOW GROUP, INC.
Option exercise · 10b5-1 plan
M$197K
8,800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Option exercise
M—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Option exercise
M—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

5
NA
Nithrakashyap ArvindDirector, Chief Technology Officer
RBRKRubrik, Inc.
Derivative conversion
C—
40.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

4
MA
Misra AmitabhChief Technology Officer
CXMSprinklr, Inc.
Open-market sale · 10b5-1 plan
SELL$243K
41.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M$12K
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
SG
Samuelson Errol GChief Industry Dev. Officer
ZANDZGZILLOW GROUP, INC.
Grant or award · 10b5-1 plan
A—
7,912 sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

3
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

3
BA
Balcom AlexandraChief Financial Officer
NUVLNuvalent, Inc.
Option exercise · 10b5-1 plan
M—
11.4K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise
M—
212.2K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$233K
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Derivative conversion
C—
212.2K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
CK
Choudary Kiran KumarChief Financial Officer
RBRKRubrik, Inc.
Option exercise
M—
7,188 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

2
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$21K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
2,896 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 26, 2026Mar 26, 2026
traded Mar 26, 2026
+0dSEC Form 4

Evidence

0
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
3,475 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
14.7K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

0
CC
Chutter Jessica CarolineDirector
PTCTPTC THERAPEUTICS, INC.
Grant or award · 10b5-1 plan
A—
4,000 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
OD
Owens Bradley D.General Counsel
ZANDZGZILLOW GROUP, INC.
Option exercise · 10b5-1 plan
M—
8,800 sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC Form 4

Evidence

0
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$107K
14.7K sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC Form 4

Evidence

56
MP
Menell Richard PeterDirector
SBSWSibanye Stillwater Ltd
Open-market purchase
BUY$29K
2,500 sh
Mar 24, 2026Mar 25, 2026
traded Mar 24, 2026
+1dSEC Form 4

Evidence

50
AJ
Angotti Vincent J.Director, CHIEF EXECUTIVE OFFICER
TLPHTALPHERA, INC.
Open-market purchase
BUY$125K
213.3K sh
Mar 13, 2026Mar 25, 2026
traded Mar 13, 2026
+12dSEC Form 4

Evidence

47
AM
Angel MatthewDirector, CEO and President, 10% Owner
TPSTTempest Therapeutics, Inc.
Open-market purchase
BUY$500K
231.5K sh
Mar 24, 2026Mar 25, 2026
traded Mar 24, 2026
+1dSEC Form 4

Evidence

44
AD
Armstrong Courtney DDirector
VRSNVERISIGN INC/CA
Open-market purchase
BUY$3,980
16 sh
Nov 25, 2025Mar 25, 2026
traded Nov 25, 2025
+120dSEC Form 4

Evidence

44
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$1.03M
12.6K sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC Form 4

Evidence

43
KC
Keyter CharlDirector, Chief Financial Officer
SBSWSibanye Stillwater Ltd
Open-market purchase
BUY$95K
35.0K sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC Form 4

Evidence

42
PC
Parker Austin ColbyCFO and Treasurer
KYNKayne Anderson Energy Infrastructure Fund, Inc.
Open-market purchase
BUY$36K
2,500 sh
Mar 25, 2026Mar 25, 2026
traded Mar 25, 2026
+0dSEC Form 4

Evidence

41
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$634K
7,749 sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC Form 4

Evidence

41
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$265K
3,162 sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC Form 4

Evidence

41
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$431K
5,140 sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC Form 4

Evidence